

Funding Opportunities

for Epidemiology and Genetics Research

<http://epi.grants.cancer.gov/funding>

The Epidemiology and Genetics Research Program (EGRP), in the National Cancer Institute's (NCI) Division of Cancer Control and Population Sciences (DCCPS), provides research opportunities to increase understanding of cancer etiology and prevention in human populations. EGRP supports epidemiologic research in four areas:

Modifiable Risk Factors—focusing on factors that may be modified to reduce cancer risk, such as diet and nutrition; alcohol; physical activity and energy balance; tobacco; infectious diseases; physical and chemical agents; and medical exposures, including medications and treatments;

Host Susceptibility Factors—focusing on factors that influence personal susceptibility to cancer, such as genetic, epigenetic, immunological, hormonal, and biological pathways; and social, cultural, and racial / ethnic factors;

Methods and Technologies—focusing on methods for epidemiologic data collection, study design and analysis, and development and adaptation of laboratory and technical approaches for large epidemiologic studies; and

Clinical and Translational Epidemiology—focusing on etiologic and genomic factors that influence cancer progression, recurrence, survival and other treatment outcomes, and factors associated with cancer development among individuals with underlying diseases and conditions.

EGRP is a sponsor, cosponsor, or a named contact for the following PAs—Program Announcements, PARs—Program Announcements with Special Review, and RFAs—Requests for Applications. For details, search the *NIH Guide for Grants and Contracts* by announcement number at <http://grants.nih.gov/grants/guide>.

Key to the grant mechanism numbers listed below: R01—Research Project Grant, R03—Small Research Grant, R21—Exploratory/Developmental Grant, U01—Cooperative Agreement, and U19—Research Program-Cooperative Agreement.

Research on Malignancies in the Context of HIV/AIDS

PA-10-290 for R01
Submission dates: January 7,
May 7, September 7

PA-10-291 for R21
Submission dates: January 7,
May 7, September 7

Both PAs expire September 8, 2013.

The purpose of these PAs is to advance our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying Human Immunodeficiency Virus (HIV) infection or Acquired Immune Deficiency Syndrome (AIDS). These PAs seek to encourage research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both AIDS-defining and non-AIDS-defining malignancies in diverse populations in the context of an underlying HIV infection. These PAs invite research efforts that will: (1) provide information on the clinical outcomes of such cancers in the HIV-infected population; and (2) identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers. *(continued next page)*

Research on Malignancies in the Context of HIV/AIDS (continued)	These PAs are cosponsored with NCI's Division of Cancer Biology (DCB), the Office of AIDS Malignancy Program, and with the National Institute of Dental and Craniofacial Research (NIDCR). For more information: (R01) http://grants1.nih.gov/grants/guide/pa-files/PA-10-290.html; (R21) http://grants1.nih.gov/grants/guide/pa-files/PA-10-291.html Contacts: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov; and Vaurice Starks, Program Director, Methods and Technologies Branch, e-mail: starksv@mail.nih.gov
Core Infrastructure and Methodological Research for Cancer Epidemiology PAR-10-283 for U01 Submission dates: March 8, July 6, November 10 Expires November 9, 2013.	This PAR invites grant applications to provide targeted infrastructure support for the core functions of cancer epidemiology cohorts (CECs) and methodological research. This infrastructure can support existing or new CECs. This PAR will support core functions for CECs currently funded through other grant mechanisms by the Epidemiology and Genetics Research Program (EGRP) and other components of NCI's Division of Cancer Control and Population Sciences (DCCPS). For more information: (U01) http://grants.nih.gov/grants/guide/pa-files/PAR-10-283.html; (FAQ) http://epi.grants.cancer.gov/funding/cohorts Contact: Deborah Winn, Ph.D., Deputy Director, DCCPS, e-mail: winnde@mail.nih.gov
Epigenetic Approaches in Cancer Epidemiology PA-10-031 for R01 Submission dates: February 5, June 5, October 5 PA-10-032 for R21 Submission dates: February 16, June 16, October 16 Both PAs expire January 8, 2013.	These PAs are to stimulate population-based epidemiology research on the roles of DNA methylation markers in cancer. The objectives are for researchers to evaluate determinants of methylation patterns, risks of cancer associated with DNA methylation, and markers and modifiers of cancer risk using epidemiologic approaches in existing human population studies. For more information: (R01) http://grants.nih.gov/grants/guide/pa-files/PA-10-031.html; (R21) http://grants.nih.gov/grants/guide/pa-files/PA-10-032.html Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov
Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis PA-10-025 for R01 Submission dates: February 5, June 5, October 5 PA-10-026 for R21 Submission dates: February 16, June 16, October 16 Both PAs expire January 8, 2013.	These PAs are to encourage researchers working in the field of cancer control and prevention to: (1) improve existing models for cancer risk and prognosis by developing innovative research projects that use existing data, (2) develop new models for cancer risk and prognosis, and (3) validate new models and evaluate their utility in research and clinical settings. The PAs provide a mechanism of support for investigators to address two major challenges in model development: integrating diverse types of data and ensuring adequate validation. NCI's Division of Cancer Control and Population Sciences (DCCPS) is cosponsoring these PAs with the Division of Cancer Treatment and Diagnosis (DCTD). For more information: (R01) http://grants.nih.gov/grants/guide/pa-files/PA-10-025.html; (R21) http://grants.nih.gov/grants/guide/pa-files/PA-10-026.html Contacts: Andrew Freedman, Ph.D., Chief, Clinical and Translational Epidemiology Branch, e-mail: freedmaa@mail.nih.gov; and Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Climate Change and Health: Assessing and Modeling Population Vulnerability to Climate Change PAR-10-235 for R21 Submission dates: May 24, 2011; May 24, 2012 Expires May 25, 2012.	This PAR invites applications to support small research projects examining the differential risk factors of populations that lead to, or are associated with, increased vulnerability to exposures, diseases, and other adverse health outcomes related to climate change. Applications may involve either applied research studies that address specific hypotheses about risk factors or population characteristics associated with increased vulnerability, or research projects to develop general models or methods for identifying and characterizing population vulnerability to climate change. The ultimate goal of this research program is to help inform climate change adaptation and public health interventions to reduce current and future vulnerability of various populations to the health effects of climate change. NCI encourages applications with the ability to incorporate long time spans to assess the impact of climate changes on cancer incidence through established physical, chemical, or infectious agents that may differentially impact populations due to their geographic location, genotype, and/or developmental windows of susceptibility. NCI joins the National Institute of Environmental Health Sciences (NIEHS) and other NIH Institutes and Centers in co-sponsoring this PAR. For more information: (R21) http://grants.nih.gov/grants/guide/pa-files/PA-10-235.html Contact: Britt C. Reid, D.D.S., Ph.D., Chief, Modifiable Risk Factors Branch, e-mail: reidbr@mail.nih.gov
Studies of Energy Balance and Cancer in Humans PA-09-148 for R01 Submission dates: February 5, June 5, October 5 PA-09-149 for R21 Submission dates: February 16, June 16, October 16 Both PAs expire May 8, 2012.	These PAs invite investigator-initiated research to define factors affecting energy balance and mechanisms influencing cancer risk, prognosis, and quality of life. These studies may range from new analyses of existing datasets to additional collection of data and biological specimens in ongoing investigations. These PAs are cosponsored with NCI's Office of Cancer Survivorship (OCS), Division of Cancer Control and Population Sciences (DCCPS), and Division of Cancer Prevention (DCP). For more information: (R01) http://grants.nih.gov/grants/guide/pa-files/PA-09-148.html; (R21) http://grants.nih.gov/grants/guide/pa-files/PA-09-149.html Contact: Somdat Mahabir, Ph.D., M.P.H., Program Director, Modifiable Risk Factors Branch, e-mail: mahabir@mail.nih.gov
Deepwater Horizon Disaster Research Consortia: Health Impacts and Community Resiliency RFA-ES-11-006 for U19 Submission date: January 21, 2011 Expires January 22, 2011.	The purpose of this RFA is to solicit applications to (1) examine the impacts of the Deepwater Horizon disaster on health, illness, and quality of life for the general population residing in the Gulf Coast region; and (2) increase the scientific evidence base needed to strengthen the resiliency of vulnerable populations along the Gulf Coast to prepare for and recover from the effects of the Deepwater Horizon and similar disasters. NCI is interested in identifying the consequences of toxic exposures related to the disaster on the sequence of events leading to cancer. It is likely that a long follow-up period and very large numbers of study participants would be needed to meaningfully assess cancer risks from disaster exposures. However, setting up the research studies now will build capacity and provide an opportunity for research on disaster-related exposures and determinants of the sequence of events, from biomarkers of exposure through early damage that might influence cancer risk, and genomic factors, such as genetic susceptibility, that may modify those biomarkers along the continuum to cancer. The National Institute of Environmental Health Sciences (NIEHS) is the lead sponsor of the RFA; several other NIH Institutes also are cosponsors. For more information: (U19) http://grants.nih.gov/grants/guide/rfa-files/RFA-ES-11-006.html Contact: Gary L. Ellison, Ph.D., M.P.H., Program Director, Modifiable Risk Factors Branch, e-mail: ellisong@mail.nih.gov

Methods and Approaches for Detection of Gene-Environment Interactions in Human Disease PAR-11-032 for R21 Submission date: February 3, 2011 Expires February 4, 2011.	This PAR encourages applications to develop and test innovative statistical, analytical, and bioinformatics methods and approaches for identifying gene-environment interactions for complex human diseases. The objectives of this PAR are to further advance the understanding of gene-environment interplay in complex human disease by (1) the development and validation of algorithms and new statistical and computational approaches and study designs, and/or (2) the development and application of bioinformatics software for gene-environment analysis of existing human populations. The long-term goal is to help identify individuals at highest risk for developing a specific disease or dysfunction based on both their exposure patterns and genetic risk profiles and inform potential environmental modifications or behavioral change interventions that could be implemented to prevent or reduce disease burden. For more information: (R21) http://grants.nih.gov/grants/guide/pa-files/PA-11-032.html Contact: Leah Mechanic, Ph.D., M.P.H., Program Director, Host Susceptibility Factors Branch, e-mail: mechanil@mail.nih.gov
Mitochondria in Cancer Epidemiology, Detection, Diagnosis, and Prognosis PA-08-143 for R01 Submission dates: February 5, June 5, October 5 PA-08-144 for R21 Submission dates: February 16, June 16, October 16 Both PAs expire May 8, 2011.	These PAs are intended to stimulate the development and validation of novel mitochondrial (mt) DNA biomarkers for understanding the etiology, early detection, diagnosis, prognosis, and risk assessment of cancer; and responses to preventive and ameliorative treatment. These PAs are cosponsored with NCI's Division of Cancer Prevention (DCP), Division of Cancer Treatment and Diagnosis (DCTD), and the Office of the Director (OD). For more information: (R01) http://grants.nih.gov/grants/guide/pa-files/PA-08-143.html; (R21) http://grants.nih.gov/grants/guide/pa-files/PA-08-144.html Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov Note: These PAs have been approved for 3 more years; see PA-11-073 (R01) at http://grants.nih.gov/grants/guide/pa-files/PA-11-073.html and PA-11-074 (R21) at http://grants.nih.gov/grants/guide/pa-files/PA-11-074.html.
Ethical, Legal, Social Implications of Human Genome Research PA-08-012 for R01 Submission dates: February 5, June 5, October 5 PA-08-013 for R03 Submission dates: February 16, June 16, October 16 Both PAs expire May 8, 2011.	These PAs invite research on the ethical, legal, and social implications (ELSI) of the discovery and use of new information and technologies resulting from human genomic research. Areas of interest include: (1) translation of genomic information to improved human health; (2) conduct of genomic research; (3) intellectual property issues surrounding access to and use of genomic information; (4) nonmedical applications of genomic technologies and information; (5) impact of genomics on concepts of race, ethnicity, kinship, and individual and group identity; (6) implications of uncovering genetic contributions to not only disease, but also “normal” human traits and behaviors; and (7) ethical boundaries for the uses of genomics. The National Human Genome Research Institute (NHGRI) is the lead sponsor of the PAs; several other NIH Institutes also are cosponsors. For more information: (R01) http://grants.nih.gov/grants/guide/pa-files/PA-08-012.html; (R03) http://grants.nih.gov/grants/guide/pa-files/PA-08-013.html Contact: Daniela Seminara, Ph.D., M.P.H., Scientific Consortia Coordinator and Program Director, Office of the Associate Director, e-mail: seminard@mail.nih.gov

Pilot Studies in Pancreatic Cancer PA-08-209 for R03 PA-08-208 for R21 Submission dates for both PAs: February 16, June 16, October 16 Both PAs expire September 8, 2011.	These trans-NCI PAs are to promote innovative research across multiple disciplines for a better understanding of the biology, etiology, detection, prevention, and treatment of pancreatic cancer. Inquiries about cancer control, epidemiology, and survivorship research proposals are handled by EGRP. For more information: (R03) http://grants.nih.gov/grants/guide/pa-files/PA-08-209.html; (R21) http://grants.nih.gov/grants/guide/pa-files/PA-08-208.html Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov
Small Grants Program for Cancer Epidemiology PAR-08-237 for R03 Submission dates: March 19, July 17, November 19 Expires November 19, 2011.	This PAR invites applications relating to cancer epidemiology with a primary focus on etiologic cancer research. These are short-term awards intended to provide support for pilot projects, testing of new techniques, or development of innovative projects that could provide a basis for more extended research. Note that this PAR stipulates a 10-page limit to the research plan, including tables and figures. For more information: (R03) http://grants.nih.gov/grants/guide/pa-files/PA-08-237.html Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Other Funding Opportunities of Interest

Extramural Training Grants (various mechanisms)

<http://www.cancer.gov/researchandfunding/training>

Diet, Epigenetic Events, and Cancer Prevention (R01 and R21)

<http://grants.nih.gov/grants/guide/pa-files/PA-09-234.html>

<http://grants.nih.gov/grants/guide/pa-files/PA-09-235.html>

Improving Diet and Physical Activity Assessment (R01 and R21)

<http://grants.nih.gov/grants/guide/pa-files/PA-09-224.html>

<http://grants.nih.gov/grants/guide/pa-files/PA-09-225.html>

Epidemiology and Genetics Research Program

Division of Cancer Control and Population Sciences

6130 Executive Boulevard, Room 5113, MSC 7395, Bethesda, MD 20892-7395

Telephone: 301-496-9600 Fax: 301-435-6609

Web site: <http://epi.grants.cancer.gov>